Peregrine Redeemed: Phase II Bavi Discrepancies Minimal
By Catherine Shaffer
Monday, January 7, 2013
Peregrine Pharmaceuticals Inc.'s internal review of vial coding discrepancies from a Phase II trial of bavituximab in non-small-cell lung cancer (NSCLC) showed that the errors were isolated to placebo and 1-mg/kg treatment arms, leaving the 3-mg/kg treatment arm unaffected.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.